Literature DB >> 25772239

WIF1 re-expression in glioblastoma inhibits migration through attenuation of non-canonical WNT signaling by downregulating the lncRNA MALAT1.

I Vassallo1,2, P Zinn3, M Lai4, P Rajakannu1,2, M-F Hamou1,2, M E Hegi1,2.   

Abstract

Glioblastoma is the most aggressive primary brain tumor in adults and due to the invasive nature cannot be completely removed. The WNT inhibitory factor 1 (WIF1), a secreted inhibitor of WNTs, is systematically downregulated in glioblastoma and acts as strong tumor suppressor. The aim of this study was the dissection of WIF1-associated tumor-suppressing effects mediated by canonical and non-canonical WNT signaling. We found that WIF1 besides inhibiting the canonical WNT pathway selectively downregulates the WNT/calcium pathway associated with significant reduction of p38-MAPK (p38-mitogen-activated protein kinase) phosphorylation. Knockdown of WNT5A, the only WNT ligand overexpressed in glioblastoma, phenocopied this inhibitory effect. WIF1 expression inhibited cell migration in vitro and in an orthotopic brain tumor model, in accordance with the known regulatory function of the WNT/Ca(2+) pathway on migration and invasion. In search of a mediator for this function differential gene expression profiles of WIF1-expressing cells were performed. Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a long non-coding RNA and key positive regulator of invasion, emerged as the top downregulated gene. Indeed, knockdown of MALAT1 reduced migration in glioblastoma cells, without effect on proliferation. Hence, loss of WIF1 enhances the migratory potential of glioblastoma through WNT5A that activates the WNT/Ca(2+) pathway and MALAT1. These data suggest the involvement of canonical and non-canonical WNT pathways in glioblastoma promoting key features associated with this deadly disease, proliferation on one hand and invasion on the other. Successful targeting will require a dual strategy affecting both canonical and non-canonical WNT pathways.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25772239     DOI: 10.1038/onc.2015.61

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  58 in total

1.  Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.

Authors:  M Enomoto; S Hayakawa; S Itsukushima; D Y Ren; M Matsuo; K Tamada; C Oneyama; M Okada; T Takumi; M Nishita; Y Minami
Journal:  Oncogene       Date:  2009-06-29       Impact factor: 9.867

2.  Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells.

Authors:  A Besson; A Davy; S M Robbins; V W Yong
Journal:  Oncogene       Date:  2001-11-01       Impact factor: 9.867

3.  The receptor tyrosine kinase Ror2 is involved in non-canonical Wnt5a/JNK signalling pathway.

Authors:  Isao Oishi; Hiroaki Suzuki; Nobuyuki Onishi; Ritsuko Takada; Shuichi Kani; Bisei Ohkawara; Ikue Koshida; Kentaro Suzuki; General Yamada; Georg C Schwabe; Stefan Mundlos; Hiroshi Shibuya; Shinji Takada; Yasuhiro Minami
Journal:  Genes Cells       Date:  2003-07       Impact factor: 1.891

4.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma.

Authors:  Anastasia Murat; Eugenia Migliavacca; Thierry Gorlia; Wanyu L Lambiv; Tal Shay; Marie-France Hamou; Nicolas de Tribolet; Luca Regli; Wolfgang Wick; Mathilde C M Kouwenhoven; Johannes A Hainfellner; Frank L Heppner; Pierre-Yves Dietrich; Yitzhak Zimmer; J Gregory Cairncross; Robert-Charles Janzer; Eytan Domany; Mauro Delorenzi; Roger Stupp; Monika E Hegi
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

5.  Wnt5a suppresses colon cancer by inhibiting cell proliferation and epithelial-mesenchymal transition.

Authors:  Runfen Cheng; Baocun Sun; Zhiyong Liu; Xiulan Zhao; Lisha Qi; Yixian Li; Qiang Gu
Journal:  J Cell Physiol       Date:  2014-12       Impact factor: 6.384

6.  Calcium regulates ERK signaling by modulating its protein-protein interactions.

Authors:  Dana Chuderland; Rony Seger
Journal:  Commun Integr Biol       Date:  2008

Review 7.  Understanding high grade glioma: molecular mechanism, therapy and comprehensive management.

Authors:  Yongzhi Wang; Tao Jiang
Journal:  Cancer Lett       Date:  2013-01-20       Impact factor: 8.679

8.  Dominant-stable beta-catenin expression causes cell fate alterations and Wnt signaling antagonist expression in a murine granulosa cell tumor model.

Authors:  Derek Boerboom; Lisa D White; Sophie Dalle; José Courty; Joanne S Richards
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

9.  Mitogen-activated protein kinase p38 regulates the Wnt/cyclic GMP/Ca2+ non-canonical pathway.

Authors:  Li Ma; Hsien-yu Wang
Journal:  J Biol Chem       Date:  2007-08-07       Impact factor: 5.157

10.  Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migration.

Authors:  Michiru Nishita; Sa Kan Yoo; Akira Nomachi; Shuichi Kani; Nagako Sougawa; Yasutaka Ohta; Shinji Takada; Akira Kikuchi; Yasuhiro Minami
Journal:  J Cell Biol       Date:  2006-11-13       Impact factor: 10.539

View more
  58 in total

1.  LncRNA GAS5 regulates the proliferation, migration, invasion and apoptosis of brain glioma cells through targeting GSTM3 expression. The effect of LncRNA GAS5 on glioma cells.

Authors:  Guoxiong Li; Yingqian Cai; Chuanmei Wang; Min Huang; Jiansheng Chen
Journal:  J Neurooncol       Date:  2019-06-06       Impact factor: 4.130

Review 2.  LncRNAs: macromolecules with big roles in neurobiology and neurological diseases.

Authors:  Ye Chen; Jun Zhou
Journal:  Metab Brain Dis       Date:  2017-02-04       Impact factor: 3.584

3.  Age-Related Expression of a Repeat-Rich Intergenic Long Noncoding RNA in the Rat Brain.

Authors:  Sukhleen Kour; Pramod C Rath
Journal:  Mol Neurobiol       Date:  2016-01-11       Impact factor: 5.590

4.  Temozolomide Treatment Induces lncRNA MALAT1 in an NF-κB and p53 Codependent Manner in Glioblastoma.

Authors:  David J Voce; Giovanna M Bernal; Longtao Wu; Clayton D Crawley; Wei Zhang; Nassir M Mansour; Kirk E Cahill; Szymon J Szymura; Abhineet Uppal; David R Raleigh; Ruben Spretz; Luis Nunez; Gustavo Larsen; Nikolai N Khodarev; Ralph R Weichselbaum; Bakhtiar Yamini
Journal:  Cancer Res       Date:  2019-04-02       Impact factor: 12.701

5.  Self-indicating, fully active pharmaceutical ingredients nanoparticles (FAPIN) for multimodal imaging guided trimodality cancer therapy.

Authors:  Xiangdong Xue; Yee Huang; Xinshuai Wang; Zhongling Wang; Randy P Carney; Xiaocen Li; Ye Yuan; Yixuan He; Tzu-Yin Lin; Yuanpei Li
Journal:  Biomaterials       Date:  2018-02-03       Impact factor: 12.479

6.  MALAT1 functions as a competing endogenous RNA to mediate Rac1 expression by sequestering miR-101b in liver fibrosis.

Authors:  Fujun Yu; Zhongqiu Lu; Jing Cai; Kate Huang; Bicheng Chen; Guojun Li; Peihong Dong; Jianjian Zheng
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

7.  An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme.

Authors:  Meng Zhou; Zhaoyue Zhang; Hengqiang Zhao; Siqi Bao; Liang Cheng; Jie Sun
Journal:  Mol Neurobiol       Date:  2017-05-19       Impact factor: 5.590

8.  lncRNA MALAT1 binds chromatin remodeling subunit BRG1 to epigenetically promote inflammation-related hepatocellular carcinoma progression.

Authors:  Mingyan Huang; Huamin Wang; Xiang Hu; Xuetao Cao
Journal:  Oncoimmunology       Date:  2018-10-16       Impact factor: 8.110

Review 9.  Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease.

Authors:  Keith Richard Mitchelson; Wen-Yan Qin
Journal:  World J Biol Chem       Date:  2015-08-26

10.  Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells.

Authors:  Ulf D Kahlert; Abigail K Suwala; Katharina Koch; Manabu Natsumeda; Brent A Orr; Masanori Hayashi; Jarek Maciaczyk; Charles G Eberhart
Journal:  J Neuropathol Exp Neurol       Date:  2015-09       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.